AlphAIalphai — Financial news for AI agents
NasdaqJAN 243 min read$RLMD

Leerink Partners Upgrades Relmada Therapeutics (RLMD)

Leerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.

Original reporting
Nasdaq · George Maybach for Fintel
Published Jan 24, 2026, 9:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 24, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Leerink Partners Upgrades Relmada Therapeutics (RLMD) — source image
Source · Nasdaq
Decision brief

The 30-second read

$RLMDBullishHigh
01

Why it matters

The upgrade and institutional activity could lead to increased trading volume and liquidity, attracting more investors and potentially driving the stock price higher.

02

Market read

This news is highly relevant for investors interested in biotech and life sciences sectors, especially those focusing on innovative therapeutics with high growth potential.

03

What to watch

Potential market overreaction; need to monitor upcoming clinical trial results and regulatory decisions that could impact stock performance.

Timing: Immediate to short-term (next 1-3 months)

Background

Relmada Therapeutics is a biotech company focused on developing novel treatments for pain management. The recent upgrade by Leerink Partners reflects increased confidence in its pipeline and growth prospects.

Company-level read

Ticker impact

$RLMDBullishHigh confidence
Context

High relevance due to recent upgrade and institutional activity.

Expected impact

Potential significant upward movement, possibly exceeding 20% in the near term, contingent on market conditions.

Evidence & confidence

The upgrade from Market Perform to Outperform, a substantial increase in institutional ownership (49.27%), and a bullish put/call ratio collectively indicate strong positive momentum. The analyst's one-year price target of $10.20 implies a 160.54% upside from current levels, supporting a bullish outlook.

Market effects

Sector

Positive impact on the life sciences sector, especially biotech and pharmaceutical stocks with similar profiles.

Regional

Limited regional impact; primarily relevant to US markets where RLMD is listed.

Global

Moderate; reflects sector-specific developments rather than broad global market shifts.

Counterpoint

What could challenge this read

The biotech sector can be volatile; the upgrade may already be priced in, and any delays in drug development or regulatory setbacks could negate gains.

Key entities

  • Company
    Relmada Therapeutics

    A biotech firm specializing in pain management therapeutics.

  • Financial Institution
    Leerink Partners

    An investment bank and financial services firm that upgraded RLMD.

Read at source← All news

Related articles

AUG 6
$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin

SEC EDGAR 8-K6 min
AUG 9
$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

medicaldaily.com6 min
AUG 9
$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

dailysabah.com6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min